Long-term Daily Use of Trazenta® Tablets in Patients With Type 2 Diabetes Mellitus

Boehringer Ingelheim

Status: Completed

Conditions: Diabetes Mellitus, Type 2

Treatments: Drug: Trazenta; Drug: OAD

Study type: Observational

Funder types: Industry

Identifiers

NCT01650259

1218.95

Details and patient eligibility

About

Study to investigate the safety and efficacy of long-term daily use of Trazenta® Tablets as monotherapy in patients with type 2 diabetes mellitus and to assess baseline characteristics of patients with type 2 diabetes mellitus starting Trazenta® Tablets or any other oral antidiabetic monotherapy (naïve or switched from prior therapy of different oral antidiabetic drug).

Enrollment: 4,876 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male and female patients with type 2 Diabetes Mellitus who have never been treated with Trazenta tablets / Linagliptin (monotherapy) before enrollment. (Trazenta group)
• Patients with type 2 Diabetes Mellitus starting any other oral antidiabetic monotherapy (naïve or switched from prior therapy of different oral antidiabetic drug (OAD)) except Trazenta tablets. (OAD group)

Exclusion criteria

None

Trial design

4,876 participants in 2 patient groups

Oral antidiabetic drug (OAD)

Treatment:

Drug: OAD

Trazenta

Treatment:

Drug: Trazenta